<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087473</url>
  </required_header>
  <id_info>
    <org_study_id>ATORG004</org_study_id>
    <nct_id>NCT04087473</nct_id>
  </id_info>
  <brief_title>Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC</brief_title>
  <official_title>Plasma Molecular Profiling in ALK Inhibitor Resistant Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guardant Health AMEA, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to understand a comprehensive molecular profiling via the plasma, with
      the primary aim of using this form on analysis to guide subsequent treatment selection. This
      study will provide a better understanding of ALK resistance in the treatment of Asian lung
      cancers and allow for improved clinical outcomes by 'matching' the secondary mutations to an
      ALK inhibitor which would allow for the greatest coverage ultimately leading to lasting
      duration of response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular profiling of plasma</measure>
    <time_frame>2 to 4 weeks after collection of plasma</time_frame>
    <description>Profiling of the collected plasma samples at a molecular level to evaluate the molecular epidemiology of ALK fusion oncogene positive lung cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient survival status</measure>
    <time_frame>After molecular profiling has been completed, every few months up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subsequent patient treatment status</measure>
    <time_frame>After molecular profiling has been completed, every few months up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes of the subsequent treatments the patients receive</measure>
    <time_frame>After molecular profiling has been completed, every few months up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>ALK-Positive Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Prior 2nd generation ALKi</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior 1st and 2nd generation ALKi</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      15-20mL of plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Two cohorts will be enrolled, the first cohort will consist of patients that have received
        prior 2nd generation ALKi only, and the second cohort with patients that have received
        prior 1st and 2nd generation ALKi.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced ALK fusion oncogene positive lung adenocarcinoma that have
             progressed after 1-2 ALK inhibitors, with at least one prior line of 2nd generation
             ALKi (i.e. Ceritinib, Alectinib, Brigatinib or Ensartinib)

          -  The availability of sufficient plasma

          -  Age ≥ 21 years

          -  WHO performance status ≤ 2

          -  Life expectancy of ≥ 21 weeks

          -  Patients should have adequate organ function for potential consideration into clinical
             trials (routine blood tests are valid within 14 days before enrollment):

               1. Adequate bone marrow function as shown by: ANC ≥ 1.0x10^9/L, Platelets ≥
                  75x10^9/L, Hb ≥ 7.5 g/dL

               2. Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range
                  (or ≤ 3.0xULN if liver metastases are present)

          -  Willing to provide signed informed consent

          -  Patients whom do not fulfill the above criteria may be discussed on a case-by-case
             basis within the study team, for potential enrolment

        Exclusion Criteria:

          -  Received more than 2 prior ALK inhibitors (ALKi)

          -  Symptomatic or uncontrolled brain metastases requiring concurrent treatment inclusive
             but not limited to surgery and radiation. Stable/ tailing doses of corticosteroids is
             permitted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel SW Tan, BS,cMBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre of Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther Koh</last_name>
    <phone>+65 6236 9460</phone>
    <email>esther.koh.h.t@nccs.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Centre</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169690</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK inhibitor (ALKi)</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Anaplastic lymphoma kinase (ALK) fusion oncogene NSCLC</keyword>
  <keyword>Guardant360 assay</keyword>
  <keyword>Next-Generation Sequencing (NGS) DNA sequencing test</keyword>
  <keyword>Cell-free circulating tumor DNA (ctDNA)</keyword>
  <keyword>Plasma profiling</keyword>
  <keyword>Blood-based assay</keyword>
  <keyword>Mutational testing</keyword>
  <keyword>74 genetic alterations (point mutations, copy number variants, fusions, insertions, deletions)</keyword>
  <keyword>ALK resistance mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

